Taken together, these data suggest that 5-HT6 receptor inverse agonists—already in clinical development for the treatment of cognitive impairment in dementia and psychoses—and strategies disrupting 5-HT6 receptor-mTOR interaction, might be new therapeutic approaches for the treatment of diabetic neuropathic pain, in addition to neuropathic pain of traumatic and toxic etiologies. The gene discussed is MTOR; the disease is dementia.